We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.

The last EIPG Newesletter is available:


  • Technology & Production
    Science Europe’s report on interdisciplinarity of research
  • Politics & Business
    The new EU Commissioners for Health and Research: proposals and suggestions for their action
  • Regulatory
    A Staff Working Document on EMA’s fees published by the EU Commission
  • Focus
    Verification, review, and check: approximation and implementation in terms of data integrity
  • EIPG
    Draft Code of Practice for Qualified Persons and other news from EIPG

More information on the EIPG website


EIPG webinar 270220

EIPG Webinar

The role of the body clock in drug development, efficacy and toxicity 

Thursday 27/02/2020

Click here to register

EIPG’s and PIER’s next webinar, presented by Dr Annie Curtis, will cover the role of the body clock in drug development, efficacy and toxicity. For centuries we have known that rhythms in our physiology exist so that our bodies stay in tune with the daily cycle, imposed by the rotation of the Earth. Twenty years ago scientists began to genetically pick apart the molecular make-up of these rhythms, and discovered that each of our cells has the capacity to tell the time of day. This has opened up a new field in biology, called chronobiology, which is the study of our body clocks in health and disease. Today, this field has begun to unpick the implications of our body clocks in terms of drug development, efficacy and toxicity. This has major implications as up to half of the 100 top selling medicines are against a target that is controlled by our molecular clock, leading to daily changes in the expression of this target. Chronotherapy has the aim of harnessing our body clocks and these subsequent rhythms to improve the efficacy and safety of drugs.

This is an event for members of EIPG member organisations, Contact your national association EIPG representative for further information.


Professional Royal Association of Pharmacists active in the Life Science Industry 

The monthly European Industrial Pharmacists’ newsletter • January 2020

  • New technologies to boost healthcare
  • Towards the Brexit’s transition phase
  • EMA’s view on Pharmacovigilance in 2030
  • Norway: initiative to lower drug prices in nine European Countries
  • Medicines Shortages at the spotlight of the European Parliament Pharma Watch

Full information on this link

EIPG2019 1This year, the General Assembly (GA) of the European Industrial Pharmacists Group (EIPG) took place in Budapest (Hungary) from 24 May to 26 May 2019. Alexia Rensonnet and Thomas Lion (board members and EIPG delegates) represented the Belgian Association.
The GA started with a scientific symposium entitled “Crossing the bridge: A current overview of the Falsified Medicines Directive” with five different speakers from the EFPIA, EIPG, Hungarian associations and companies. Piero Iamartino from EIPG presented the draft of the guidance on “Safety features implementation and QP responsibilities”.

During the GA, the Belgian Association UPIP-VAPI was mentioned several times and recognized for its pertinent contribution to the work of EIPG; for instance, for the review of QP code of conduct, a part concerning the good distribution practices (GDP) was added thanks to Belgium or for the contribution to the newsletter from EIPG in February. Moreover, Belgium is also well represented among the members visiting EIPG website or taking part in the proposed webinars.EIPG2019 2
During the GA, two working groups were also organized on Saturday. The first was entitled: “Professional Codes of Conduct and Legislation Requirements” and discussed the following question “What is the position of the industrial pharmacist in today’s industry?” and compared the requirements in the legislation for the different positions in the pharmaceutical industry in function of the countries in the European Union. For example, in the Belgian legislation, the role of the pharmacist is well mentioned and described which is not the case in all other countries. The goal of the discussion was to determine “How can we defend the pharmacist further in the European regulation?”.

The second was entitled: “Competences and Industrial Pharmacy Education” and considered the competences needed for the industrial pharmacist in the future following the new trends in the industry.

On the last day, Belgium presented to the other countries the activities organized by our association (UPIP-VAPI is one of the most active European associations) but also the hot topics in Belgium in our sector: drug shortages and the new Belgian law, the implementation of the falsified medicines directive in our country with the transition period, the increase of clinical trials and the pressure on the solidarity health insurance.

The next GA will take place in Leiden in May 2020.


FAGG-AFMPS is issuing its annual report that you can discover in the documents attached on the links below.

The minutes of the Strategies & Qualification methodologies for Visual Inspection meeting

The minutes are here (pdf)

Seminar on “New and Emerging Regulations”,

Sldeshows and minutes

A survey on potential future role for pharmacists in the pharmaceutical industry

Our Newsletter is available !

Read it now!

UPIP-VAPI was a union of industrial pharmacists, but in the meantime has adjusted its statutes to become a platform for all pharmacists active in the pharmaceutical industry and for those interested in its activities.